Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Goodbye IMI, Hello IHI: New EU Partnership Prepares To Invite Research Proposals

Broadened membership includes medtech and digital health

Executive Summary

The new iteration of the EU’s successful public-private R&D partnership promises to increase the support for medtech and digital platforms as well pharmaceutical research, with the aim of producing innovative cross-sectoral projects in areas such as drug/device combinations and AI-based diagnostics.

You may also be interested in...

Devices, Diagnostics, Digital & Drugs: Europe’s New R&D Venture Presents Its Agenda

The EU’s new public-private partnership, the Innovative Health Initiative, plans to involve a wide range of stakeholders in research projects aimed at developing new drugs, diagnostics and medical devices. At its launch event this week, two of its top officials described how the venture would work, who could get involved, and the challenges in doing so.

Medtech’s Place In Health Care R&I Boosted Under Horizon Europe

Cross-industry collaboration is the new focus of EU health care technology research funding activity. Under Horizon Europe, the Innovative Health Initiative will encourage convergence in health technology, and prioritize digital technologies and data analytics. No longer can EU-funded projects be pharma-only or medtech-only, said MedTech Europe’s Patrick Boisseau.

EU Falsified Medicines Directive ‘Not Working’ In Northern Ireland

Industry representatives told a House of Lords committee about continuing Brexit-related problems such as the extra work involved in checking compliance with the EU Falsified Medicines Directive and the drawbacks of a proposed “dual regulatory regime.”


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts